GHRP-6
Animal studies onlyGet notified when the evidence changes.
Almost all the research is in animals. We do not know if the same thing happens in people.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-05-14
Also called Growth Hormone Releasing Peptide 6 / SKF-110771
Similar to GHRP-2. Known for strongly increasing hunger in animal studies.
Official status: 503A Category 3 – nominated without adequate support · Checked 2026-05-14
Can a doctor prescribe this?
- Small pharmacy (503A)
- Category 3 — not enough evidence sent in
- Large outsourcing facility (503B)
- Category 2 — FDA flagged a safety concern
The FDA has "GHRP-6" in Category 3 of the substances put forward for small-pharmacy (503A) compounding: someone did put it forward, but what was sent in did not include enough evidence for the FDA to judge it.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 10
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
- Study in peopleA discovery-based proteomic approach of epidermal growth factor and growth hormone-releasing peptide-6 in a model of acute ischemic stroke.
Pharmacological reports : PR · 2026
- Study in peoplePhase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2026
- Study in peopleHexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.
Psychoneuroendocrinology · 2004
- Study in peoplePhysical activity or food intake prior to testing did not affect the reproducibility of GH secretion elicited by GH releasing hormone plus GH-releasing hexapeptide in normal adult subjects.
Clinical endocrinology · 2002
- Study in peopleEffects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
Clinical endocrinology · 2001
- Study in peopleAcute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man.
Clinical endocrinology · 1999
- Study in peopleThe effect of an opiate antagonist on the hormonal changes induced by hexarelin.
Clinical endocrinology · 1995
- Study in peopleGrowth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.
The Journal of clinical endocrinology and metabolism · 1993
- Data from people, not a trialAnterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.
Frontiers in surgery · 2026
- Data from people, not a trialDifferent effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism.
Clinical endocrinology · 1997
- Animal study, rats or miceGrowth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis.
International immunopharmacology · 2026
- Animal study, rats or miceGrowth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation.
Pharmaceuticals (Basel, Switzerland) · 2026
- Animal study, rats or miceGhrelin impairs embryo development after ovarian hyperstimulation.
The Journal of endocrinology · 2026
- Animal study, rats or miceActivation of the nucleus nuclear factor erythroid 2-related factor 2ghrelin/growth hormone secretagogue receptor 1a signaling by Yueju pill confers cardioprotective and antidepressant effects.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
- Animal study, rats or miceEGF and GHRP6 Co-Administration Attenuates Cognitive Decline in Preclinical Models: Behavioral and Molecular Evidences.
Neurotoxicity research · 2026
- Animal study, rats or miceThe Ghrelin/GHSR-1a Axis Attenuates Preeclampsia-like Features with Decidual Macrophage Reprogramming and Improved Placental Remodeling.
Biomolecules · 2026
- Animal study, larger animalsGhrelin attenuates hypoxia-induced mitochondrial oxidative stress damage in HTR-8/SVneo trophoblasts.
Tissue & cell · 2026
- Animal study, rats or miceGrowth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Journal of nanobiotechnology · 2025
- Animal study, rats or miceChanges in Locomotor Activity Observed During Acute Nicotine Withdrawal Can Be Attenuated by Ghrelin and GHRP-6 in Rats.
Biomedicines · 2025
- Dog studySubchronic safety assessment of CIGB-500 in beagle dog after repeated daily dose administration over 28 days.
Regulatory toxicology and pharmacology : RTP · 2025
- Animal study, rats or miceIntranasal Delivery of a Ghrelin Mimetic Engages the Brain Ghrelin Signaling System in Mice.
Endocrinology · 2025
- Animal study, rats or miceGrowth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
Frontiers in pharmacology · 2024
- Animal study, larger animalsInhibition of ghrelin activity by the receptor antagonist [D-Lys3]-GHRP-6 enhances hepatic fatty acid oxidation and gluconeogenesis in a growing pig model.
Peptides · 2023
- Animal study, larger animalsGhrelin antagonist D-Lys3-GHRP-6 counteract ghrelin effects in bovine cumulus-oocytes complexes matured in vitro.
Reproduction in domestic animals = Zuchthygiene · 2021
- Animal study, rats or miceAtheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice.
Atherosclerosis · 2020
- Animal study, rats or miceD-Lys-3-GHRP-6 impairs memory consolidation and downregulates the hippocampal serotonin HT1A, HT7 receptors and glutamate GluA1 subunit of AMPA receptors.
Physiology & behavior · 2020
- Animal study, rats or miceLimited short-term effects on human prostate cancer xenograft growth and epidermal growth factor receptor gene expression by the ghrelin receptor antagonist [D-Lys<sup>3</sup>]-GHRP-6.
Endocrine · 2019
- Animal study, rats or miceInhibition of Ghrelin Activity by Receptor Antagonist [d-Lys-3] GHRP-6 Attenuates Alcohol-Induced Hepatic Steatosis by Regulating Hepatic Lipid Metabolism.
Biomolecules · 2019
- Animal study, rats or miceLocal injection of d-lys-3-GHRP-6 in the rat amygdala, dentate gyrus or ventral tegmental area impairs memory consolidation.
Neuropeptides · 2018
- Animal study, rats or miceLong-term treatment with the ghrelin receptor antagonist [d-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice.
American journal of physiology. Regulatory, integrative and comparative physiology · 2018
- Animal study, rats or miceImpact of [d-Lys(3)]-GHRP-6 and feeding status on hypothalamic ghrelin-induced stress activation.
Peptides · 2016
- Animal study, larger animalsInsulinotropic action of bombesin-like peptides mediated by gastrin-releasing peptide receptors in steers.
Journal of animal science · 2016
- Animal study, rats or miceThe effects of ghrelin antagonists [D-Lys(3) ]-GHRP-6 or JMV2959 on ethanol, water, and food intake in C57BL/6J mice.
Alcoholism, clinical and experimental research · 2014
- Animal study, rats or miceThe effect of ghrelin antagonist (D-Lys3) GHRP-6 on ovariectomy-induced obesity in adult female albino rats.
Endocrine regulations · 2014
- Animal study, rats or miceAmyloid beta lowering and cognition enhancing effects of ghrelin receptor analog [D-Lys (3)] GHRP-6 in rat model of obesity.
Indian journal of biochemistry & biophysics · 2014
- Animal study, rats or miceRole of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats.
Iranian journal of kidney diseases · 2014
- Animal study, rats or miceGastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6.
World journal of gastroenterology · 2012
- Animal study, rats or miceProtective effect of GHRP-6 and estrogen supplementation against some cardiometabolic risk factors in ovariectomized rats.
Endocrine regulations · 2012
- Animal study, larger animalsBombesin-like peptides stimulate growth hormone secretion mediated by the gastrin-releasing peptide receptor in cattle.
Peptides · 2012
- Animal study, rats or miceGhrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats.
Alzheimer disease and associated disorders · 2011
- Dog studyEffects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism.
Molecular and cellular endocrinology · 2002
- Studied in worms or fishEffect of intracerebroventricular (ICV) injection of antimicrobial peptide expressed in the body-2 (LEAP-2) and its interaction with cannabinoid and ghrelin systems on food intake in broiler chickens.
Poultry science · 2026
- Studied in worms or fishOral administration of the growth hormone secretagogue-6 (GHRP-6) enhances growth and non-specific immune responses in tilapia (Oreochromis sp.)
Aquaculture. · 2016
- Lab dish studyAssessing The Effectiveness of Growth Hormone Releasing Protein-6 in Improving Human Oocyte Maturation and Meiotic Progression in <i>In Vitro</i> Maturation Culture Media.
International journal of fertility & sterility · 2025
- Lab dish studyPotassium Current Is Not Affected by Long-Term Exposure to Ghrelin or GHRP-6 in Somatotropes GC Cells.
Journal of biophysics (Hindawi Publishing Corporation : Online) · 2013
- Lab dish studyIdentification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist.
International journal of biological sciences · 2012
- Lab dish studyThe GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist.
International journal of medical sciences · 2012
- Lab dish studyGrowth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism.
Clinical endocrinology · 1997
- Lab test method, not a health studyDetection of GHRP-2 and GHRP-6 in urine samples from athletes.
Drug testing and analysis · 2015
- Lab test method, not a health studyDevelopment and validation of a bioanalytical LC-MS method for the quantification of GHRP-6 in human plasma.
Journal of pharmaceutical and biomedical analysis · 2012
- Chemistry or materials paper, not a health studyAza-Isotryptophan: Synthesis, Pictet-Spengler Chemistry, Incorporation and Conformational Analysis in Peptides, and Activity in Modulators of the Cluster of Differentiation-36 Receptor.
Journal of medicinal chemistry · 2025
- Oral salmon acylated ghrelin increases food intake in common carp (Cyprinus carpio) via ghrelin receptors, likely through sensory nerves rather than systemic absorption.
Peptides · 2026
- The Ghrelin Analog GHRP-6, Delivered Through Aquafeeds, Modulates the Endocrine and Immune Responses of <i>Sparus aurata</i> Following IFA Treatment.
Biology · 2025
- Ghrelin Downregulates Lipopolysaccharide/ Leptin-Induced MUC5AC Expression in Human Nasal Epithelial Cells.
Clinical and experimental otorhinolaryngology · 2023
- Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy.
Neurological research · 2016
- [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.
Molecular and cellular endocrinology · 2015
- Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2013
- Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment.
Pituitary · 2010
- Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2010
- Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6).
Clinical endocrinology · 2010
- Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus.
Metabolism: clinical and experimental · 2010
- Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis.
Pituitary · 2009
- Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients.
European journal of endocrinology · 2008
- Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
Pituitary · 2007
- Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.
Pituitary · 2006
- Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp.
Diabetes research and clinical practice · 2004
- GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.
Journal of endocrinological investigation · 2003
- GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal.
Journal of endocrinological investigation · 2003
- Growth-hormone response to combined stimulation with GHRH plus GH-releasing peptide-6 in obese patients with polycystic ovary syndrome before and after short-term fasting.
Journal of endocrinological investigation · 2003
- Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
European journal of endocrinology · 2003
- Effects of short-term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing peptide-6: studies in normal men and in patients with adrenal insufficiency.
The Journal of clinical endocrinology and metabolism · 2000
- GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.
Lancet (London, England) · 2000
- Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration.
Journal of neuroendocrinology · 1999
- Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.
Metabolism: clinical and experimental · 1999
- Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
Journal of endocrinological investigation · 1999
- Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6.
The Journal of clinical endocrinology and metabolism · 1998
- Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation.
The Journal of clinical endocrinology and metabolism · 1998
- Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release.
Clinical endocrinology · 1997
- Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients.
Clinical endocrinology · 1996
- Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
The Journal of clinical endocrinology and metabolism · 1996
- Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
The Journal of clinical endocrinology and metabolism · 1996
- Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
Clinical endocrinology · 1995
- Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature.
European journal of endocrinology · 1995
- Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
The Journal of clinical endocrinology and metabolism · 1995
- Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.
Neuroendocrinology · 1995
- Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.
The Journal of endocrinology · 1995
- Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency.
European journal of endocrinology · 1995
- Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
Journal of endocrinological investigation · 1994
- Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging.
European journal of endocrinology · 1994
- Review of earlier workThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Frontiers in endocrinology · 2026
Spot an error? corrections@peptidesearch.org
What has happened so far
- 14 May 2026503A
FDA lists "GHRP-6" under 503A Category 3: Bulk Drug Substances Nominated Without Adequate Support. Read from the FDA 503A category document headed "Updated May 14, 2026".
- 21 March 2025503B
FDA lists "GHRP-6" under 503B Category 2: Bulk Drug Substances that Raise Significant Safety Risks. Outsourcing facilities are not to compound it. Read from the FDA 503B category document dated March 21, 2025.